<DOC>
	<DOCNO>NCT00681122</DOCNO>
	<brief_summary>This observational study restrict postmenopausal woman hormone-sensitive early breast cancer , decide take prescribed adjuvant use AIs , anastrozole letrozole , accord current product SmPCs . There Investigational Medicinal Product ( IMP ) take observational study . The adjuvant AI medication must exceed thirteen week . In CARIATIDE ( Compliance ARomatase Inhibitors AssessmenT In Daily practicE Educational approach ) , impact educational material woman 's compliance persistence rate evaluate .</brief_summary>
	<brief_title>CARIATIDE ( Compliance ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach )</brief_title>
	<detailed_description />
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Postmenopausal woman hormone sensitive early breast cancer Documented decision treatment upfront adjuvant AI ( either anastrozole letrozole ) accord current SmPC OR current treatment AI ( either anastrozole letrozole ) accord current SmPC , exceed thirteen week Upfront adjuvant AI medication exceed thirteen week randomisation Concomitant adjuvant treatment tamoxifen exemestane Previous use adjuvant tamoxifen exemestane exceed thirteen week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>aromatase inhibitor</keyword>
</DOC>